Cell Therapy News/Articles, page-354

Watch video ......,
New post on The Stem Cellar


Stem Cell Agency Awards Almost $4 Million to Develop a Treatment for Spinal Degeneration
by Yimy Villa

Today the
governing Board of the California Institute for Regenerative Medicine (CIRM)
awarded $3.9 million to Ankasa Regenerative Therapeutics for a promising approach to treat a
degenerative condition that can cause chronic, progressive back pain.

As we get
older, the bones, joints and ligaments in our back become weak and less able to
hold the spinal column in alignment.  As
a result, an individual vertebral bone in our spine may slip forward over the
one below it, compressing the nerves in the spine, and causing lower back pain
or radiating pain.  This condition,
called degenerative spondylolisthesis, primarily affects individuals over the
age of 50 and, if left untreated, can cause intense pain and further
degeneration of adjacent regions of the spine.

Current
treatment usually involves taking bone from one of the patient’s other bones,
and moving it to the site of the injury.
The transplanted bone contains stem cells necessary to generate new
bone.  However, there is a caveat to this
approach— as we get older the grafts become less effective because the stem
cells in our bones are less efficient at making new bone.  The end result is little or no bone
healing.

Ankasa has developed ART352-L, a protein-based drug product
meant to enhance the bone healing properties of these bone grafts.  ART352-L works by stimulating bone stem cells
to  increase the amount of bone produced
by the graft.

The award is in the form of a CLIN1 grant, with the goal of
completing the testing needed to apply to the Food and Drug Administration
(FDA) for permission to start a clinical trial in people.

This is a project that CIRM has supported through earlier
phases of research.

“We are excited to see the development that this approach has made since its early stages and reflects our commitment to supporting the most promising science and helping it advance to the clinic,” says Maria T. Millan, MD, President & CEO of CIRM. “There is an unmet medical need in older patients with bone disorders such as degenerative spondylolisthesis.  As our population ages, it is important for us to invest in potential treatments such as these that can help alleviate a debilitating condition that predisposes to additional and fatal medical complications."

See the animated video below for a descriptive and visual synopsis of degenerative spondylolisthesis.



watch video ...,Cheers